CoreMap
CoreMap is a private, pre-commercial medical device company developing ultra-high resolution electroanatomical mapping systems (Invenio catheter and VidereX workstation) for atrial fibrillation treatment, serving cardiac electrophysiologists in hospital EP labs.
- Company typePrivate
- Founded2016
- HeadquartersBurlington, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CoreMap does
CoreMap is a private medical device company founded in 2016 by Dr. Peter Spector, a practicing clinical electrophysiologist, that develops ultra-high resolution electroanatomical mapping systems for the diagnosis and treatment of atrial fibrillation (AF). The company's system comprises the Invenio cardiac mapping catheter and the VidereX mapping workstation, designed to be used together during electrophysiology (EP) procedures in hospital catheterization labs. CoreMap's core technical differentiator is a tissue property mapping approach rather than conventional activation mapping, enabled by an orthogonal bipolar electrode configuration on the catheter that allows sequential data acquisition without the sample-density limitations of competing systems. The platform generates novel maps of atrial fibrillation using statistical analysis of data acquired from the ultra-high-resolution catheter.
CoreMap is pre-commercial and has not yet generated product revenue. The expected business model follows the standard EP lab device commercial pattern, with the Invenio catheter positioned as a single-use disposable and the VidereX workstation as installed capital equipment in EP labs at hospitals performing AF ablations; the target customer segment is practicing cardiac electrophysiologists and their EP lab teams. CoreMap holds ISO 13485 certification and received FDA Investigational Device Exemption (IDE) approval in May 2025 for the INvENI Map-Guided AF Ablation Study, positioning the company to begin U.S. clinical enrollment as a precursor to a future premarket approval (PMA) submission and commercial launch. CoreMap is headquartered in Burlington, Vermont, with an additional office in Burlington, Massachusetts, and operates with a headcount of 11–50 employees spanning engineering, data science, clinical, and regulatory functions.
CoreMap firmographics
Firmographics- Name
- CoreMap
- Legal name
- CoreMap Inc.
- Website
- https://coremapmedical.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CoreMap is a private, pre-commercial medical device company developing ultra-high resolution electroanatomical mapping systems (Invenio catheter and VidereX workstation) for atrial fibrillation treatment, serving cardiac electrophysiologists in hospital EP labs.
- Ownership category
- akta.pro rank
CoreMap industry classification
Industry- Product category
- Cardiac Electrophysiology Mapping Systems
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Other Measuring and Controlling Device Manufacturing (334519)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Industrial Instruments For Measurement, Display, And Control (3823)
- akta.pro industry
- Electrophysiology Mapping & Ablation SystemsHealthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
Keywords
Where CoreMap is headquartered
LocationHeadquarters
- HQ city
- Burlington
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
CoreMap business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: CoreMap is developing an electrophysiological mapping system (catheter and workstation) for atrial fibrillation treatment. The company is in pre-commercial stage with FDA IDE approval for clinical studies. Revenue will be generated through sale of the mapping system to hospitals and electrophysiology labs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
CoreMap product offering
Product offeringCore offering
CoreMap is developing an advanced electrophysiological mapping system for atrial fibrillation treatment, consisting of the Invenio catheter (a high-resolution cardiac catheter with proprietary micro-electrodes) and the VidereX workstation (data processing and visualization platform). The system uses ultra-high resolution micro-electrode technology to map tissue properties rather than activation patterns, enabling electrophysiologists to identify AF drivers and deliver patient-specific ablation therapy. The device is currently investigational and not yet commercially available.
Product overview
CoreMap offers a unified electroanatomical mapping platform for atrial fibrillation treatment. The system comprises two primary components: the Invenio catheter (an ultra-high resolution cardiac catheter with proprietary micro-electrode design for mapping tissue properties) and the VidereX workstation (for data processing and visualization). Together, these products enable identification of AF drivers and patient-specific treatment planning by generating high-resolution 3D electroanatomical maps during cardiac procedures. The company focuses on overcoming the limitations of traditional activation mapping through tissue property mapping that can be acquired sequentially, effectively eliminating sample density constraints.
Differentiator
Problem solved
Functional benefit
Products and services
- Invenio Catheter A high-resolution cardiac catheter with proprietary ultra-high resolution micro-electrodes designed to capture detailed electrical properties of atrial tissue and identify atrial fibrillation drivers during cardiac ablation procedures. The catheter is intended for electrophysiologists performing AF ablation in hospital electrophysiology labs and is currently limited to investigational use.
- VidereX Workstation A workstation component of CoreMap's mapping system that processes and visualizes catheter data to enable electrophysiologists to identify AF drivers and support personalized, patient-specific treatment planning during cardiac ablation procedures. Currently limited to investigational use.
- 3D Electroanatomical Mapping System A high-resolution, real-time 3D electroanatomical mapping system for use during cardiac procedures to guide ablation therapy. The system generates novel maps of atrial fibrillation using statistical analysis of data acquired from the Invenio ultra-high-resolution cardiac catheter, addressing the spatial resolution and sample density limitations of conventional mapping technologies. Currently investigational.
Quantifiable outcome
- CoreMap's ultra-high resolution electrodes reveal details of activation despite fibrillation complexity
Companies that use CoreMap
Customer profileSegments1 record
Ideal customer profiles1 record
CoreMap technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
CoreMap partnerships and signals
Strategic signalScale indicators4 records
Recent moves5 records
Expansion highlights4 records
CoreMap competitors and assessment
Company assessmentDirect peers
- Biosense Webster (Johnson & Johnson): Market-leading EP mapping and ablation franchise (CARTO 3 system) and CoreMap's primary direct competitor in cardiac electrophysiology mapping. Competes head-to-head for EP lab capital equipment and ablation catheter share.
- Boston Scientific: Developer of the Rhythmia HDx mapping system and a broad ablation catheter portfolio. Directly competes with CoreMap in 3D electroanatomical mapping and AF ablation procedures.
- Abbott: Markets the EnSite X EP system and Advisor ablation catheters. One of the three dominant EP mapping competitors and a direct comparable to CoreMap's Invenio + VidereX platform.
Emerging players
- Acutus Medical: Pre-revenue/early-commercial competitor in high-resolution EP mapping with non-contact dipole charge-density mapping. Comparable as a smaller, technologically differentiated EP mapping peer targeting AF and complex arrhythmias.
- Volta Medical: AI-based EP decision-support and mapping company focused on AF ablation. Comparable as a venture-stage peer leveraging data-driven approaches to improve AF procedural outcomes.
- Kardium: Developer of the Globe mapping and ablation system for AF. Direct emerging competitor pursuing a single-shot, all-in-one mapping and ablation workflow that overlaps with CoreMap's EP lab thesis.
- Adagio Medical: Developer of ultra-low-temperature cryoablation technology for AF and VT. Comparable as a venture-stage competitor focused on persistent AF, an indication CoreMap's tissue-property mapping also targets.
- APN Health: Non-invasive 3D cardiac arrhythmia mapping company. Comparable as a smaller peer pursuing advanced mapping methodologies to improve ablation targeting and procedural efficiency.
- CathVision: Developer of AI-enabled EP recording and signal-processing systems used during ablation procedures. Comparable as an emerging player whose signal-quality and analytics focus overlaps with CoreMap's mapping-workstation strategy.
Broad incumbents
- Medtronic: Broad cardiac device incumbent with a cryoablation franchise and an evolving EP mapping presence. Provides strategic context as a potential acquirer or channel partner for CoreMap.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
CoreMap social profiles
Digital presenceCoreMap compliance and trust
Trust signalCompliance1 record
CoreMap financial estimates
Financial estimateRevenue estimate
Valuation estimate
CoreMap leadership team
Management profileNumber of profiles
Profiles9 records
CoreMap funding detail
Funding detailFunding overview
Funding rounds9 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CoreMap M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CoreMap
What does CoreMap do?
CoreMap is developing an advanced electrophysiological mapping system for atrial fibrillation treatment, consisting of the Invenio catheter (a high-resolution cardiac catheter with proprietary micro-electrodes) and the VidereX workstation (data processing and visualization platform). The system uses ultra-high resolution micro-electrode technology to map tissue properties rather than activation patterns, enabling electrophysiologists to identify AF drivers and deliver patient-specific ablation therapy. The device is currently investigational and not yet commercially available.
Is CoreMap a public or private company?
CoreMap is a private company. It is classified as venture growth investor backed and is currently operating.
When was CoreMap founded?
CoreMap was founded in 2016. It employs 11 to 50 people.
Where is CoreMap based?
CoreMap is headquartered in Burlington, United States, in the North America region.
How does CoreMap make money?
One revenue line is on record: medical Device Sales.
Who are CoreMap's main competitors?
Direct peers on record are Biosense Webster (Johnson & Johnson), Boston Scientific and Abbott. Emerging players are Acutus Medical, Volta Medical, Kardium, Adagio Medical, APN Health and CathVision. Medtronic is listed as a broad incumbent.
Does CoreMap have an API?
No public API is recorded for CoreMap.
What industry is CoreMap in?
CoreMap's product category is Cardiac Electrophysiology Mapping Systems. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems. Its NAICS code is 334510 and its SIC code is 3845.